The company has so far filed seven DMFs with the US FDA. Announcing this along with the second quarter financial results of the company, N Prasad, the chairman and chief executive officer, said the company had 30 products in the pipeline for launch in the regulated markets such as US, Europe and Canada before 2010, as and when patents expire for those products.
Prasad hoped that the company would get a significant share of business from the recently concluded agreement of William J Clinton Presidential Foundation with four companies (Ranbaxy, Cipla, and the South African Aspen Pharmacare besides Matrix) for supply of anti-AIDS bulk drugs for its initiative in African countries to offer treatment to two million patients in five years.
